RE: 2x RNS1 Apr 2025 07:21
I dont see any material impact on IMM share price based on these RNSs.
***ImmuPharma Warrant Extension (Incanthera)***
ImmuPharma’s warrants to buy 7.27 million Incanthera shares at 9.5p have been extended to 30 September 2025.
In return, ImmuPharma will pay 30% of any profit made when selling these shares after exercising the warrants.
This gives ImmuPharma more time to benefit from potential price increases in Incanthera shares.
***Debt Conversion & Equity Issue (Incanthera)***
Incanthera is issuing new shares (4.47 million) at 8.5p each to settle £380,000 in debts.
This includes £260,000 owed to the University of Bradford, which will now own 11.05% of Incanthera’s shares.
Additional shares are being issued to advisers in exchange for £120,000 in fees.
Total shares in circulation will rise to 121.37 million after the new issue.
*** Impact on IMM Share Price ***
Positive: Extending the warrants gives ImmuPharma another chance to profit from Incanthera’s potential growth.
Negative: Issuing more shares dilutes existing shareholders' value, which might pressure Incanthera’s share price.
Neutral to Slightly Positive: If Incanthera performs well, IMM benefits indirectly. However, no immediate impact is expected unless IMM exercises the warrants.